GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (NAS:EXEL) » Definitions » Price-to-Owner-Earnings

Exelixis (Exelixis) Price-to-Owner-Earnings

: 48.42 (As of Today)
View and export this data going back to 2000. Start your Free Trial

As of today (2024-04-19), Exelixis's share price is $22.275. Exelixis's Owner Earnings per Share (TTM) ended in Dec. 2023 was $0.46. It's Price-to-Owner-Earnings for today is 48.42.


The historical rank and industry rank for Exelixis's Price-to-Owner-Earnings or its related term are showing as below:

EXEL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.63   Med: 40.42   Max: 620.42
Current: 48.99

During the past 13 years, the highest Price-to-Owner-Earnings of Exelixis was 620.42. The lowest was 7.63. And the median was 40.42.


EXEL's Price-to-Owner-Earnings is ranked worse than
66.1% of 177 companies
in the Biotechnology industry
Industry Median: 33.62 vs EXEL: 48.99

As of today (2024-04-19), Exelixis's share price is $22.275. Exelixis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.64. Therefore, Exelixis's PE Ratio for today is 34.64.

As of today (2024-04-19), Exelixis's share price is $22.275. Exelixis's EPS without NRI for the trailing twelve months (TTM) ended in was $0.70. Therefore, Exelixis's PE Ratio without NRI for today is 31.69.

During the past 13 years, Exelixis's highest PE Ratio without NRI was 148.62. The lowest was 12.19. And the median was 26.76.


Exelixis Price-to-Owner-Earnings Historical Data

The historical data trend for Exelixis's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exelixis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.21 82.25 26.45 66.01 52.73

Exelixis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 66.01 - 92.32 - 52.73

Competitive Comparison

For the Biotechnology subindustry, Exelixis's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exelixis Price-to-Owner-Earnings Distribution

For the Biotechnology industry and Healthcare sector, Exelixis's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Exelixis's Price-to-Owner-Earnings falls into.



Exelixis Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Exelixis's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=22.275/0.46
=48.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Exelixis  (NAS:EXEL) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Exelixis Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Exelixis's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Exelixis (Exelixis) Business Description

Traded in Other Exchanges
Address
1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Executives
Patrick J. Haley officer: Sr. Vice President, Commercial 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Jeffrey Hessekiel officer: EVP and General Counsel 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
David Edward Johnson director 590 MADISON AVENUE, NEW YORK NY 10022
Dana Aftab officer: CSO/EVP Disc & Trans Research EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Amy C. Peterson officer: EVP Prod Dev & Med Aff & CMO C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Christopher J. Senner officer: EVP and CFO 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Tomas J. Heyman director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Bob Oliver director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Caligan Partners Lp director, other: See Remarks 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Jack L Wyszomierski director SCHERING PLOUGH CORP, ONE GIRALDA FARMS, MADISON NJ 07940-1000
Alan M Garber director 3355 MILTON COURT, MOUNTAIN VIEW CA 94040
Carl B Feldbaum director C/O EXELIXIS INC, 170 HARBOR WAY, PO BOX 511, SOUTH SAN FRISCISCO CA 94083-0511
Peter Lamb officer: EVP, Discovery Research & CSO PO BOX 511, 170 HARBOR WAY, SOUTH SAN FRANCISCO CA 94083-0511
George Poste director 515 GALVESTON DR, REDWOOD CITY CA 94063
Lance Willsey director C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083

Exelixis (Exelixis) Headlines

From GuruFocus

Exelixis Announces $550 Million Share Repurchase Program

By Business Wire Business Wire 03-20-2023